DK1833840T3 - Micromirs - Google Patents

Micromirs

Info

Publication number: DK1833840T3
Authority: DK; Denmark
Prior art keywords: lna; deoxynucleotide; designates; lna nucleotide; subscript
Prior art date: 2004-11-09

Application number

DK05800760.0T

Other languages

English (en)

Inventor

Frank Winther Rasmussen

Majken Westergaard

Henrik Frydenlund Hansen

Charlotte Albaek Thrue

Original Assignee

Santaris Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-09

Filing date

2005-11-09

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36177326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1833840(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-11-09 Application filed by Santaris Pharma As filed Critical Santaris Pharma As

2010-10-18 Application granted granted Critical

2010-10-18 Publication of DK1833840T3 publication Critical patent/DK1833840T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 2
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05800760.0T 2004-11-09 2005-11-09 Micromirs DK1833840T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US62656304P	2004-11-09	2004-11-09
US64718605P	2005-01-25	2005-01-25
US69972105P	2005-07-15	2005-07-15
US72462105P	2005-10-07	2005-10-07
PCT/DK2005/000721 WO2006050734A2 (en)	2004-11-09	2005-11-09	Potent lna oligonucleotides for the inhibition of hif-1a expression

Publications (1)

Publication Number	Publication Date
DK1833840T3 true DK1833840T3 (da)	2010-10-18

Family

ID=36177326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05800760.0T DK1833840T3 (da)	2004-11-09	2005-11-09	Micromirs

Country Status (16)

Country	Link
US (3)	US7589190B2 (da)
EP (1)	EP1833840B9 (da)
JP (3)	JP4825807B2 (da)
KR (1)	KR101176245B1 (da)
AT (1)	ATE476441T1 (da)
AU (1)	AU2005304112B2 (da)
BR (1)	BRPI0515726A8 (da)
CA (1)	CA2587173C (da)
DE (1)	DE602005022768D1 (da)
DK (1)	DK1833840T3 (da)
EA (1)	EA014097B1 (da)
IL (1)	IL183054A0 (da)
MX (1)	MX2007005558A (da)
NO (1)	NO341878B1 (da)
NZ (1)	NZ555644A (da)
WO (1)	WO2006050734A2 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2752488T3 (da)	2002-11-18	2020-04-20	Roche Innovation Ct Copenhagen As	Antisense-design
US7144999B2 (en) *	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
ES2576677T3 (es)	2003-03-21	2016-07-08	Roche Innovation Center Copenhagen A/S	Análogos de ARN interfirientes cortos
DK1713912T3 (da) *	2004-01-30	2013-12-16	Santaris Pharma As	Modificerede Korte Interfererende RNA (Modificerede siRNA)
NZ555644A (en) *	2004-11-09	2009-04-30	Santaris Pharma As	Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US9447138B2 (en)	2004-11-09	2016-09-20	Roche Innovation Center Copenhagen A/S	Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP1976567B1 (en)	2005-12-28	2020-05-13	The Scripps Research Institute	Natural antisense and non-coding rna transcripts as drug targets
CA2638837A1 (en) *	2006-01-27	2007-08-02	Santaris Pharma A/S	Lna modified phosphorothiolated oligonucleotides
WO2007107162A2 (en) *	2006-03-23	2007-09-27	Santaris Pharma A/S	Small internally segmented interfering rna
WO2007136989A2 (en)	2006-05-05	2007-11-29	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of dgat2
EP2076257A4 (en) *	2006-09-15	2014-04-16	Belrose Pharma Inc	POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
DK2149605T3 (da) *	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2149605B1 (en)	2007-03-22	2013-07-03	Santaris Pharma A/S	Short RNA antagonist compounds for the modulation of target mRNA
CN101868251B (zh) *	2007-08-06	2012-10-10	千寿制药株式会社	含有HIF-1α和HIF-2α表达抑制物质的药物
DK2195428T3 (da)	2007-09-19	2014-03-03	Applied Biosystems Llc	Sirna sekvens-uafhængige modifikationsformater til reducering af target-forfejlende fænotypiske effekter ved rnai, og stabiliserede former deraf
CA2701895A1 (en) *	2007-10-04	2009-04-09	Santaris Pharma A/S	Short rna antagonist compounds for the modulation of hif1alpha
US8153606B2 (en)	2008-10-03	2012-04-10	Opko Curna, Llc	Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
CA2746003C (en)	2008-12-04	2020-03-31	Opko Curna, Llc	Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CN102317458B (zh)	2008-12-04	2018-01-02	库尔纳公司	通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
EP2370582B1 (en)	2008-12-04	2017-05-10	CuRNA, Inc.	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
PT2396038E (pt)	2009-02-12	2016-02-19	Curna Inc	Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
CA2755409C (en)	2009-03-16	2019-04-30	Joseph Collard	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (ja)	2009-03-17	2016-04-20	クルナ・インコーポレーテッド	デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
JP6250930B2 (ja)	2009-05-06	2017-12-20	クルナ・インコーポレーテッド	トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
EP2427553A4 (en)	2009-05-06	2012-11-07	Opko Curna Llc	TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
CN102459597B (zh)	2009-05-08	2020-06-30	库尔纳公司	通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
ES2664590T3 (es)	2009-05-18	2018-04-20	Curna, Inc.	Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
CN102695797B (zh)	2009-06-16	2018-05-25	库尔纳公司	通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
KR101807324B1 (ko)	2009-06-26	2017-12-08	큐알엔에이, 인크.	다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
WO2011011700A2 (en)	2009-07-24	2011-01-27	Curna, Inc.	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
KR101802536B1 (ko)	2009-08-05	2017-11-28	큐알엔에이, 인크.	인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
WO2011019815A2 (en)	2009-08-11	2011-02-17	Curna, Inc.	Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8791087B2 (en)	2009-08-21	2014-07-29	Curna, Inc.	Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
CN102482671B (zh)	2009-08-25	2017-12-01	库尔纳公司	通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
CN102791861B (zh)	2009-09-25	2018-08-07	库尔纳公司	通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病
AR078770A1 (es)	2009-10-27	2011-11-30	Elara Pharmaceuticals Gmbh	Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101823702B1 (ko)	2009-12-16	2018-01-30	큐알엔에이, 인크.	막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
DK2516648T3 (da)	2009-12-23	2018-02-12	Curna Inc	Behandling af hepatocytvækstfaktor- (hgf) relaterede sygdomme ved hæmning af naturligt antisense-transskript mod hgf
KR101793753B1 (ko)	2009-12-23	2017-11-03	큐알엔에이, 인크.	커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
CN102770540B (zh)	2009-12-29	2017-06-23	库尔纳公司	通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
ES2657452T3 (es)	2009-12-29	2018-03-05	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
RU2016115782A (ru)	2009-12-31	2018-11-28	Курна, Инк.	Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
DK2521784T3 (da)	2010-01-04	2018-03-12	Curna Inc	Behandling af interferon regulatorisk faktor 8- (irf8) relaterede sygdomme ved hæmning af naturligt antisense-transskript mod irf8
WO2011085066A2 (en)	2010-01-06	2011-07-14	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
CA2786535C (en)	2010-01-11	2019-03-26	Curna, Inc.	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
US8946182B2 (en)	2010-01-25	2015-02-03	Curna, Inc.	Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
JP5976548B2 (ja)	2010-02-22	2016-08-23	カッパーアールエヌエー，インコーポレイテッド	Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
TWI600759B (zh)	2010-04-02	2017-10-01	可娜公司	藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
US9044494B2 (en)	2010-04-09	2015-06-02	Curna, Inc.	Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9089588B2 (en)	2010-05-03	2015-07-28	Curna, Inc.	Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP3299464B1 (en)	2010-05-26	2019-10-02	CuRNA, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP2576784B1 (en)	2010-05-26	2017-11-15	CuRNA, Inc.	Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
US8716258B2 (en) *	2010-06-04	2014-05-06	The Board Of Regents, The University Of Texas System	Regulation of metabolism by miR-378
JP6023705B2 (ja)	2010-06-23	2016-11-09	カッパーアールエヌエー，インコーポレイテッド	ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
US8993533B2 (en)	2010-10-06	2015-03-31	Curna, Inc.	Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
WO2012054723A2 (en)	2010-10-22	2012-04-26	Opko Curna Llc	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en)	2010-11-18	2012-05-24	Opko Curna Llc	Antagonat compositions and methods of use
EP2643463B1 (en)	2010-11-23	2017-09-27	CuRNA, Inc.	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012082765A2 (en)	2010-12-16	2012-06-21	The United State Of America. As Represented By The Secretary Department Of Health And Human Services	Methods for decreasing body weight and treating diabetes
EP2673361B1 (en)	2011-02-08	2016-04-13	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP2718439B1 (en)	2011-06-09	2017-08-09	CuRNA, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2753317B1 (en)	2011-09-06	2020-02-26	CuRNA, Inc.	TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
HK1210211A1 (en)	2012-03-15	2016-04-15	科纳公司	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
SG11201503821YA (en) *	2012-11-15	2015-06-29	Roche Innovation Ct Copenhagen As	Oligonucleotide conjugates
RU2690935C2 (ru) *	2013-06-04	2019-06-06	Президент Энд Фэллоуз Оф Харвард Коллидж	Направляемая рнк регуляция транскрипции
EP3472348B1 (en) *	2016-06-17	2022-06-29	F. Hoffmann-La Roche AG	In vitro nephrotoxicity screening assay
JP7012033B2 (ja)	2016-06-17	2022-02-10	エフ．ホフマン－ラロシュアーゲー	インビトロ腎毒性スクリーニングアッセイ
WO2018160772A1 (en)	2017-02-28	2018-09-07	The United State Of America, As Represented By The Secretary, Department Of Health & Human Services	Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601676B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
US5108921A (en) *	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5278324A (en)	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US6030954A (en) *	1991-09-05	2000-02-29	University Of Connecticut	Targeted delivery of poly- or oligonucleotides to cells
US5250683A (en)	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en)	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5272171A (en)	1992-02-13	1993-12-21	Bristol-Myers Squibb Company	Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr)	1992-03-13	1994-05-06	Rhone Poulenc Rorer Sa	Procede de preparation de derives du taxane.
US5248796A (en)	1992-06-18	1993-09-28	Bristol-Myers Squibb Company	Taxol derivatives
US5254580A (en)	1993-01-19	1993-10-19	Bristol-Myers Squibb Company	7,8-cyclopropataxanes
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5801154A (en)	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5882914A (en)	1995-06-06	1999-03-16	The Johns Hopkins University School Of Medicine	Nucleic acids encoding the hypoxia inducible factor-1
US6770748B2 (en)	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
US5994076A (en)	1997-05-21	1999-11-30	Clontech Laboratories, Inc.	Methods of assaying differential expression
KR100414936B1 (ko)	1997-09-12	2004-01-13	엑시콘 에이/에스	이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
US6238921B1 (en)	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
WO1999048916A2 (en)	1998-03-27	1999-09-30	The Board Of Trustees Of The Leland Stanford Jr. University	Hypoxia-inducible human genes, proteins, and uses thereof
US6821724B1 (en)	1998-09-17	2004-11-23	Affymetrix, Inc.	Methods of genetic analysis using nucleic acid arrays
CA2368135C (en)	1999-03-18	2010-06-08	Exiqon A/S	Xylo-lna analogues
WO2000056746A2 (en)	1999-03-24	2000-09-28	Exiqon A/S	Improved synthesis of [2.2.1]bicyclo nucleosides
US6350868B1 (en)	1999-04-26	2002-02-26	University Of North Carolina At Chapel Hill	Antisense human fucosyltransferase sequences and methods of use thereof
PT1178999E (pt)	1999-05-04	2007-06-26	Santaris Pharma As	Análogos de l-ribo-lna
JP4638098B2 (ja)	1999-06-14	2011-02-23	キャンサー・リサーチ・テクノロジー・リミテッド	癌治療
AU768904B2 (en)	1999-06-21	2004-01-08	Murdoch Childrens Research Institute, The	A method for the prophylaxis and/or treatment of medical disorders
US6168950B1 (en)	1999-07-23	2001-01-02	Isis Pharmaceuticals, Inc.	Antisense modulation of MEKK1 expression
CA2385853A1 (en)	1999-10-04	2001-04-12	Exiqon A/S	Design of high affinity rnase h recruiting oligonucleotide
US6706505B1 (en)	2000-03-08	2004-03-16	Amgen Inc	Human E3α ubiquitin ligase family
NZ524894A (en)	2000-09-02	2005-03-24	Gruenenthal Chemie	Antisense oligonucleotides against VR1
DK1334109T3 (da)	2000-10-04	2006-10-09	Santaris Pharma As	Forbedret syntese af purin-blokerede nukleinsyre-analoger
US7105656B2 (en)	2000-10-26	2006-09-12	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2002317437A1 (en)	2001-05-18	2002-12-03	Cureon A/S	Therapeutic uses of lna-modified oligonucleotides in infectious diseases
DE60232443D1 (de)	2001-06-05	2009-07-09	Masahiro Hiraoka	Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US7153954B2 (en)	2001-07-12	2006-12-26	Santaris Pharma A/S	Method for preparation of LNA phosphoramidites
AU2002328792A1 (en)	2001-07-12	2003-01-29	Santaris Pharma A/S	Method for preparation of lna phosphoramidites
ES2649817T3 (es)	2002-04-05	2018-01-15	Roche Innovation Center Copenhagen A/S	Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
WO2003095467A1 (en)	2002-05-08	2003-11-20	Santaris Pharma A/S	Synthesis of locked nucleic acid derivatives
KR20120038546A (ko) *	2002-11-01	2012-04-23	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
DK2752488T3 (da)	2002-11-18	2020-04-20	Roche Innovation Ct Copenhagen As	Antisense-design
US7144999B2 (en) *	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
AU2004209599A1 (en)	2003-02-10	2004-08-19	Santaris Pharma A/S	Oligomeric compounds for the modulation of ras expression
WO2004069991A2 (en)	2003-02-10	2004-08-19	Santaris Pharma A/S	Oligomeric compounds for the modulation of survivin expression
NZ555644A (en) *	2004-11-09	2009-04-30	Santaris Pharma As	Potent LNA oligonucleotides for the inhibition of HIF-1A expression

2005
- 2005-11-09 NZ NZ555644A patent/NZ555644A/en not_active IP Right Cessation
- 2005-11-09 AT AT05800760T patent/ATE476441T1/de not_active IP Right Cessation
- 2005-11-09 CA CA2587173A patent/CA2587173C/en not_active Expired - Fee Related
- 2005-11-09 JP JP2007539463A patent/JP4825807B2/ja not_active Expired - Fee Related
- 2005-11-09 DE DE602005022768T patent/DE602005022768D1/de not_active Expired - Lifetime
- 2005-11-09 WO PCT/DK2005/000721 patent/WO2006050734A2/en not_active Ceased
- 2005-11-09 BR BRPI0515726A patent/BRPI0515726A8/pt not_active Application Discontinuation
- 2005-11-09 EA EA200701033A patent/EA014097B1/ru not_active IP Right Cessation
- 2005-11-09 EP EP05800760A patent/EP1833840B9/en not_active Expired - Lifetime
- 2005-11-09 DK DK05800760.0T patent/DK1833840T3/da active
- 2005-11-09 US US11/271,686 patent/US7589190B2/en not_active Expired - Fee Related
- 2005-11-09 KR KR1020077012303A patent/KR101176245B1/ko not_active Expired - Fee Related
- 2005-11-09 AU AU2005304112A patent/AU2005304112B2/en not_active Ceased
- 2005-11-09 MX MX2007005558A patent/MX2007005558A/es unknown
2007
- 2007-05-08 IL IL183054A patent/IL183054A0/en not_active IP Right Cessation
- 2007-06-08 NO NO20072933A patent/NO341878B1/no not_active IP Right Cessation
2009
- 2009-06-03 US US12/477,261 patent/US7939507B2/en active Active
2011
- 2011-04-04 US US13/079,525 patent/US8410071B2/en not_active Expired - Fee Related
- 2011-08-15 JP JP2011177731A patent/JP2011229540A/ja not_active Withdrawn
2014
- 2014-02-21 JP JP2014031436A patent/JP2014098027A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2587173A1 (en)	2006-05-18
JP4825807B2 (ja)	2011-11-30
EP1833840A2 (en)	2007-09-19
US7939507B2 (en)	2011-05-10
DE602005022768D1 (de)	2010-09-16
US20090286859A1 (en)	2009-11-19
WO2006050734A2 (en)	2006-05-18
KR20070094891A (ko)	2007-09-27
ATE476441T1 (de)	2010-08-15
CA2587173C (en)	2016-09-06
AU2005304112A1 (en)	2006-05-18
JP2011229540A (ja)	2011-11-17
NO20072933L (no)	2007-06-08
US8410071B2 (en)	2013-04-02
KR101176245B1 (ko)	2012-08-22
US7589190B2 (en)	2009-09-15
WO2006050734A3 (en)	2006-08-03
BRPI0515726A (pt)	2008-08-05
NZ555644A (en)	2009-04-30
EA200701033A1 (ru)	2007-12-28
MX2007005558A (es)	2008-01-31
US20060252721A1 (en)	2006-11-09
EP1833840B9 (en)	2010-11-10
EA014097B1 (ru)	2010-08-30
US20110183931A1 (en)	2011-07-28
JP2008518608A (ja)	2008-06-05
IL183054A0 (en)	2007-09-20
JP2014098027A (ja)	2014-05-29
EP1833840B1 (en)	2010-08-04
AU2005304112B2 (en)	2009-06-04
NO341878B1 (no)	2018-02-12
BRPI0515726A8 (pt)	2017-09-12

Publication	Publication Date	Title
DK1833840T3 (da)	2010-10-18	Micromirs
EP1578933A4 (en)	2007-09-19	COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
Griffey et al.	1996	2 ‘-O-Aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides
UA125963C2 (uk)	2022-07-20	Олігонуклеотид для індукції батьківської експресії ube3a
ES2530671T3 (es)	2015-03-04	Silenciamiento de genes
MX2021012126A (es)	2022-01-06	Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
CY1108944T1 (el)	2014-07-02	Θεραπευτικη χρηση των tgf-βητα2 αντινοηματικων ολιγονουκλεοτιδιων
WO2005089287A3 (en)	2006-11-30	Methods and compositions for the specific inhibition of gene expression by double-stranded rna
IL176320A0 (en)	2006-10-05	Oligomeric compounds for the modulation of bcl-2
WO2009017803A8 (en)	2009-08-06	Antisense microrna and uses therefor
EP1937278A4 (en)	2009-08-12	ANTIVIRAL ANTISENSE COMPOUND AND METHOD FOR THE TREATMENT OF PICORNAVIRUS INFECTION
ATE477337T1 (de)	2010-08-15	Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
CA2453301A1 (en)	2003-01-30	Synthetic double-stranded oligonucleotides for specific inhibition of gene expression
MXPA05011221A (es)	2006-02-17	Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.
RU2013102545A (ru)	2014-09-10	Связывающая vegfa си-рнк и способы лечения in vivo
RU2015155332A (ru)	2017-06-27	Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение
PE20212248A1 (es)	2021-11-24	Molecula oligomerica de acido nucleico y uso de esta
RU2016131028A (ru)	2018-04-17	Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения
UA93188C2 (ru)	2011-01-25	Эффективные олигонуклеотиды lna для ингибирования экспрессии hif-1a
Langkjær et al.	2015	Watson–Crick hydrogen bonding of unlocked nucleic acids
Furukawa et al.	2008	Fluorescence generation from tandem repeats of a malachite green RNA aptamer using rolling circle transcription
Fujimoto et al.	2014	Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner
Torrence et al.	2006	Evaluation of synthetic oligonucleotides as inhibitors of West Nile virus replication
WO2023015153A3 (en)	2023-04-13	ANTISENSE OLIGONUCLEOTIDE TARGETING APOE ε4 AND USES THEREOF
ATE428786T1 (de)	2009-05-15	Antisense-oligonukleotid mit antikrebsaktivität